ReviewHypertension research : official journal of the Japanese Society of Hypertension2026
Hypertension: a missing piece in HFpEF?
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As population aging accelerates and unhealthy lifestyle habits become increasingly prevalent, the burden of heart failure with preserved ejection fraction (HFpEF) continues to rise. Hypertension, obesity, and atrial fibrillation (AF) are major contributors to the development and progression of HFpEF. Among these risk factors, hypertension serves as a central hub linking cardiovascular and metabolic abnormalities. This review discusses the relationship between hypertension and HFpEF, focusing on sympathovagal imbalance as a common mechanism underlying hypertension, obesity, and AF. We summarize evidence regarding the contribution of autonomic dysregulation to HFpEF pathogenesis and examine the therapeutic potential of targeting autonomic function. Current evidence suggests that a systolic blood pressure target of <130 mmHg may be appropriate for patients with HFpEF. In addition to established pharmacological therapies, emerging neuromodulatory approaches, particularly low-level transcutaneous tragus stimulation, may represent promising adjunctive treatment strategies. Improved understanding of these interrelated mechanisms may facilitate more individualized management of HFpEF.
Indexed as
Identifiers
42855530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.